ATE391496T1 - Geschmacksmaskierte pharmazeutische formulierungen - Google Patents

Geschmacksmaskierte pharmazeutische formulierungen

Info

Publication number
ATE391496T1
ATE391496T1 AT02723243T AT02723243T ATE391496T1 AT E391496 T1 ATE391496 T1 AT E391496T1 AT 02723243 T AT02723243 T AT 02723243T AT 02723243 T AT02723243 T AT 02723243T AT E391496 T1 ATE391496 T1 AT E391496T1
Authority
AT
Austria
Prior art keywords
flavor
masked pharmaceutical
pharmaceutical formulations
microcapsule
taste
Prior art date
Application number
AT02723243T
Other languages
English (en)
Inventor
Stephen Ulrich
Karen Zimm
Original Assignee
Ortho Mcneil Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ortho Mcneil Pharm Inc filed Critical Ortho Mcneil Pharm Inc
Application granted granted Critical
Publication of ATE391496T1 publication Critical patent/ATE391496T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53831,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0087Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1635Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT02723243T 2001-03-05 2002-02-26 Geschmacksmaskierte pharmazeutische formulierungen ATE391496T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US27347301P 2001-03-05 2001-03-05

Publications (1)

Publication Number Publication Date
ATE391496T1 true ATE391496T1 (de) 2008-04-15

Family

ID=23044085

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02723243T ATE391496T1 (de) 2001-03-05 2002-02-26 Geschmacksmaskierte pharmazeutische formulierungen

Country Status (12)

Country Link
US (1) US6767557B2 (de)
EP (1) EP1370247B1 (de)
JP (1) JP2004520420A (de)
AT (1) ATE391496T1 (de)
AU (1) AU2002254036A1 (de)
BR (1) BR0207932A (de)
CA (1) CA2440069A1 (de)
DE (1) DE60226012T2 (de)
HK (1) HK1058482A1 (de)
MX (1) MXPA03008057A (de)
MY (1) MY129317A (de)
WO (1) WO2002069939A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0207930A (pt) * 2001-03-05 2004-03-02 Ortho Mcneil Pharm Inc Composições farmacêuticas lìquidas com sabor mascarado
FR2821747B1 (fr) * 2001-03-09 2004-07-02 Ethypharm Lab Prod Ethiques Suspension de telithromycine a gout masque
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
MY140561A (en) 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
WO2003084518A2 (fr) 2002-04-09 2003-10-16 Flamel Technologies Suspension orale de microcapsules de principes actifs
CA2480824A1 (fr) * 2002-04-09 2003-10-16 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee d'amoxicilline
KR101179012B1 (ko) 2003-03-10 2012-09-03 니코메드 게엠베하 로플루미라스트 신규한 제조 방법
US20060228410A1 (en) * 2003-08-11 2006-10-12 Hubert Dumont Flavored taste-masked pharmaceutical formulation made using a one-step coating process
US20060013834A1 (en) * 2004-02-24 2006-01-19 Medicis Pediatrics, Inc. Room temperature stable aqueous liquid pharmaceutical composition
US20060127479A1 (en) * 2004-10-08 2006-06-15 Natrajan Kumaraperumal Solvent free taste masked pharmaceutical compositions
AU2006224619B2 (en) 2005-03-16 2012-06-07 Takeda Gmbh Taste masked dosage form containing roflumilast
US20060216355A1 (en) * 2005-03-28 2006-09-28 Donald Spector Encapsulated pharmaceuticals in a medium having non-encapsulated flavoring agents
EP1888025B1 (de) * 2005-06-08 2020-08-12 Basf Corporation Medikamententrägerzusammensetzung und verfahren zur bildung eines films daraus
US20070264335A1 (en) * 2006-05-09 2007-11-15 Sherman Bernard C Modified release tablets comprising tramadol
US8637076B2 (en) * 2006-06-01 2014-01-28 Cima Labs Inc. Prednisolone salt formulations
US20070281014A1 (en) * 2006-06-01 2007-12-06 Cima Labs, Inc. Prednisolone salt formulations
US8007783B2 (en) * 2006-08-22 2011-08-30 Carl Miller Quality of life for hepatitis C patients with a formulation for administration to the oral mucosa including Lactobacillus delbrueckii subsp. bulgaricus and N-acetyl D-glucosamine
US8304226B2 (en) * 2006-08-22 2012-11-06 Carl Miller Quality of life of hepatitis C patients with a formulation for administration to the oral mucosa including freeze dried lysate of selected Lactobacillus or Bifidobacterium species and N-acetyl D-glucosamine
WO2008098586A1 (en) * 2007-02-13 2008-08-21 Dafra Pharma N.V. Pharmaceutical carrier composition and pharmaceutical composition
WO2008155589A2 (en) * 2007-06-18 2008-12-24 Dolhay Klinika Egészségügyi Kft. Biocide capsules, preparation comprising them and sanitary pad comprising the preparation
US20090065225A1 (en) * 2007-09-07 2009-03-12 Black & Decker Inc. Switchable anti-lock control
BRPI1009121A2 (pt) * 2009-03-04 2018-06-19 Orexo Ab formulações resistentes a abuso
CN102421419B (zh) 2009-05-08 2016-05-04 奥瑞克索股份公司 用于持续药物传递的包含地聚合物粘合剂的组合物
US20110236494A1 (en) * 2010-03-04 2011-09-29 Ranbaxy Laboratories Limited Ciprofloxacin oral suspension
NZ603545A (en) 2010-04-12 2013-10-25 Zhaveri Pharmakem Pvt Ltd S Ciprofloxacin dry syrup composition
JP5843864B2 (ja) 2010-09-07 2016-01-13 オレクソ・アクチエボラゲット 経皮薬物投与デバイス
CN103813807B (zh) 2011-09-30 2017-02-08 持田制药株式会社 易服用性固体制剂
JP6632802B2 (ja) 2012-01-16 2020-01-22 マッケンナ,エリザベス 肝疾患及び肝障害を治療するための組成物及び方法
EP2898073A4 (de) 2012-09-21 2016-03-23 Elizabeth Mckenna Natürlich vorkommende cpg-oligonukleotidzusammensetzungen und therapeutische anwendungen davon
CN105050588B (zh) 2013-03-15 2019-01-15 阿普雷奇亚制药有限责任公司 托吡酯的快速分散剂型
CA2906107C (en) 2013-03-15 2021-08-24 Aprecia Pharmaceuticals Company Rapidly dispersible dosage form of oxcarbazepine
US10098964B2 (en) 2015-03-12 2018-10-16 The Board Of Trustees Of The University Of Illinois Inclusion complexes and methods for making the same
JP6294400B2 (ja) * 2016-07-19 2018-03-14 持田製薬株式会社 易服用性固形製剤
US20220016074A1 (en) 2018-11-21 2022-01-20 Rosemont Pharmaceuticals Limited Oral topiramate suspension formulations with extended shelf stability and enhanced bioavailability
EP3984529A4 (de) * 2019-06-17 2022-08-10 Towa Pharmaceutical Co., Ltd. Maskierungsteilchen mit zeitgesteuerter elution und diese enthaltende orale pharmazeutische zusammensetzung

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2068402C (en) 1991-06-14 1998-09-22 Michael R. Hoy Taste mask coatings for preparation of chewable pharmaceutical tablets
US5599556A (en) 1991-12-31 1997-02-04 Abbott Laboratories Prolamine coatings for taste masking
DE4200821A1 (de) 1992-01-15 1993-07-22 Bayer Ag Geschmacksmaskierte pharmazeutische mittel
DE19631084A1 (de) * 1996-08-01 1998-02-05 Basf Ag Verwendung von (Meth)acrylsäure-Copolymeren zur Erhöhung der Permeabilität der Schleimhaut
CN1195500C (zh) * 1998-05-18 2005-04-06 武田药品工业株式会社 可口腔崩解的片剂
WO2000006122A1 (en) * 1998-07-31 2000-02-10 Otsuka Pharmaceutical Co., Ltd. Pharmaceutical composition having improved taste
AU4943000A (en) * 1999-06-11 2001-01-02 Ranbaxy Laboratories Limited Taste masked compositions
IN192159B (de) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd

Also Published As

Publication number Publication date
US20020197327A1 (en) 2002-12-26
JP2004520420A (ja) 2004-07-08
WO2002069939A3 (en) 2003-03-13
AU2002254036A1 (en) 2002-09-19
HK1058482A1 (en) 2004-05-21
DE60226012T2 (de) 2009-05-14
DE60226012D1 (de) 2008-05-21
MXPA03008057A (es) 2004-10-15
EP1370247B1 (de) 2008-04-09
CA2440069A1 (en) 2002-09-12
WO2002069939A2 (en) 2002-09-12
MY129317A (en) 2007-03-30
US6767557B2 (en) 2004-07-27
BR0207932A (pt) 2004-03-02
EP1370247A2 (de) 2003-12-17

Similar Documents

Publication Publication Date Title
ATE391496T1 (de) Geschmacksmaskierte pharmazeutische formulierungen
WO2002011702A3 (en) Hydrogel-driven drug dosage form
AR024492A1 (es) Formas de dosificacion farmaceutica para liberacion controlada que comprenden al menos un impulso ciclico
YU35302A (sh) Dozirani oblik leka sa inicijalnim hidrogelom
AP1748A (en) Chronotherapeutic dosage forms.
SE9704869D0 (sv) New pharmaceutical formulaton II
HUP0301887A3 (en) Multi-particulate form of medicament, comprising at least two differently coated forms of pellet
ID27504A (id) Formulasi oral baru
BR0109925A (pt) Composição de revestimento para mascaramento de paladar
ATE239454T1 (de) Orale morphinzubereitung in teilchenform
DK1276470T3 (da) Smagskaskerende overtrækssammensætning
WO2001062236A3 (en) New drug combinations comprising a norepinephrine reuptake inhibitor and an antimuscarinic agent
WO2002024174A3 (en) Sustained release composition containing clarithromycin
WO2005027843A3 (en) Chronotherapeutic dosage forms
WO2004052345A8 (en) Coating composition for taste masking coating and methods for their application and use
NO20031409D0 (no) Ionestyrkeuavhengig farmasöytiske preparat med langvarig frigivelse
WO2005009410A3 (en) Pharmaceutical compositions having a swellable coating
ITMI20001093A0 (it) Composizioni a rilascio controllato contenenti un principio attivo, preferibilmente melatonina, e processo di preparazione delle stesse.
EA200300110A1 (ru) Композиция элетриптана в виде частиц
CL2012000406A1 (es) Gránulo de liberación controlada que comprende una partícula central que contiene al isómero r-lansoprazol y una capa de recubrimiento de liberación controlada soluble dependiente del ph seleccionada de copolímeros s y l del ácido metacrílico (div. sol. nº 2051-2003).
NO20040205L (no) Farmasøytiske preparater inneholdende ionebytterharpikser belagt med virksomt stoff
WO2002062299A3 (en) Improved controlled release oral dosage form
AR033431A1 (es) Composiciones farmaceuticas de sabor enmascarado.
WO2003105811A8 (en) PROGRESSIVE RELEASE COMPOSITIONS AND METHOD OF USE
IL152751A0 (en) Optically active 2-aminotetralin derivatives, the processes for the preparation thereof and the therapeutical use of pharmaceutical compositions containing them

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties